News
UM Brain Disorder Research Moves Toward Clinical Testing – Promentis Pharmaceuticals, Inc.
February 10, 2015 /
University of Montana is one step closer to turning a discovery into a drug.
Promentis Pharmaceuticals, Inc. http://www.promentispharma.com/ recently announced it will enter an exclusive agreement with UM to commercialize a discovery made by a team of UM faculty scientists that has the potential to treat brain cancer and possibly other disorders of the central nervous system.
The team, which is based in the Department of Biomedical and Pharmaceutical Sciences within UM’s Skagg’s School of Pharmacy, includes professors Richard Bridges, Sarjubhai Patel, Nicjholas Natale, Philippe Diaz and Charles Thompson.
MATR Supporters (view all)
Sorry, we couldn't find any posts. Please try a different search.